AGA Releases Irritable Bowel Syndrome Drug Treatment Guideline

AGA Releases Irritable Bowel Syndrome Drug Treatment Guideline
The American Gastroenterological Association (AGA) has released a new guideline that includes recommendations on drugs for the treatment of irritable bowel syndrome (IBS). The document, which was recently published in the Gastroenterology journal, aims to help patients as well as physicians decide the best treatments for the disease's symptoms, and the association believes that it provides an evidence-based tool to improve patients' health. The expert team responsible for the new guidelines examined data from recently published IBS studies in order to evaluate the ones they believed offered the best data quality, as well as a balance between the risks and benefits that support the use of a particular drug. The researchers used the Institute of Medicine's Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to conduct this evaluation. "Because no IBS therapy is uniformly effective, many patients describe a history of a variety of treatments alone or in combination. This guideline will help patients and physicians navigate the drug options. It's also important to consider other clinically relevant information, such as a patient's values and preferences, when making treatment decisions," explained one of the authors of the guideline, Shahnaz Sultan, who is an assistant professor of medicine at the University of Florida College of Medicine and the Department of Veteran Affairs Medical Center of the North Florida/South Georgia Veterans Health System. Irritable bowel syndrome comprises a series of symptoms affecting the function of the gastrointestinal tract, including cramps, gas, bloating, changes in bowel habits, constipation, and diarrhea. The causes are unknown, but it can lead to the development of more severe diseas
Subscribe or to access all post and page content.